Antiseizure medications

Sanders, Sean

doi:10.1002/9781118689691.ch7

Cited by 1 publication

(1 citation statement)

References 214 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although in some textbooks 13,27,28 ZNS administration for cats was described to be once a day, in this study we carried out administration every 12 h to reduce the risk of the peak concentration of a single administration exceeding the safety zone (40 μg/ml) and diurnal variation of the blood concentration depending on the ZNS dose. In addition, because some textbooks 13,27,28 indicate 5–10 mg/kg q24h for cats and because of our limited clinical experience of the use of ZNS, we started with a 2.5 mg/kg dose q12h (= 5 mg/kg/day). However, since the plasma concentration did not reach 10 µg/ml, we elevated the dose to 5.0 mg/kg q12h.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of zonisamide on interictal electroencephalography in familial spontaneous epileptic cats

Ukai

Hamamoto

et al. 2017

Journal of Feline Medicine and Surgery

View full text Add to dashboard Cite

Objectives The effectiveness of zonisamide (ZNS) against spontaneous epilepsy in cats has not yet been described. The purpose of this study was to investigate the effect of ZNS on interictal paroxysmal discharges (PDs) using scalp electroencephalography (EEG) in familial spontaneous epileptic cats (FSECs). Methods Eight FSECs were evaluated (six males and two females). Scalp EEG measurements were performed once a week for 3 weeks before ZNS administration (Pre-ZNS). Thereafter, administration of ZNS was started and an adjustment period was instituted until the drug in plasma achieved the steady state. When ZNS in plasma was confirmed to be within 10-40 μg/ml, scalp EEG measurements were performed once a week for 3 weeks (Post-ZNS). The number of PDs (counts/min) were compared between Pre-ZNS and Post-ZNS treatment. Results The median number of PDs for Pre-ZNS and Post-ZNS were 0.43/min (0.13-0.82/min) and 0.28/min (0.07-0.87/min), respectively. The number of PDs Post-ZNS was significantly reduced compared with Pre-ZNS ( P = 0.02). Conclusions and relevance This study showed that ZNS, within the recommended therapeutic range suggested for use in humans and dogs (10-40 µg/ml), reduced the number of PDs recorded on EEG in FSECs that are considered a model for cats with idiopathic epilepsy. Although phenobarbital is the antiepileptic drug of choice for epileptic cats, the results of this research provide evidence to support the use of ZNS in cats with phenobarbital-resistant epilepsy or for cats that cannot use phenobarbital due to adverse side effects.

show abstract